Capital Advisors Inc. OK Grows Holdings in Amgen Inc. (NASDAQ:AMGN)

Capital Advisors Inc. OK lifted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 13.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,404 shares of the medical research company’s stock after buying an additional 278 shares during the quarter. Capital Advisors Inc. OK’s holdings in Amgen were worth $627,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of AMGN. Capital Performance Advisors LLP acquired a new stake in shares of Amgen in the third quarter worth approximately $25,000. Legacy Investment Solutions LLC acquired a new position in shares of Amgen in the 3rd quarter valued at $29,000. Heck Capital Advisors LLC acquired a new position in shares of Amgen in the 4th quarter valued at $36,000. Wingate Wealth Advisors Inc. purchased a new stake in shares of Amgen during the 4th quarter valued at $52,000. Finally, Livelsberger Financial Advisory acquired a new stake in shares of Amgen during the 3rd quarter worth $56,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insider Activity

In other Amgen news, SVP Nancy A. Grygiel sold 1,589 shares of Amgen stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the transaction, the senior vice president now directly owns 7,210 shares in the company, valued at $2,195,228.70. The trade was a 18.06 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Jonathan P. Graham sold 25,045 shares of the company’s stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $293.12, for a total value of $7,341,190.40. Following the transaction, the executive vice president now directly owns 28,987 shares of the company’s stock, valued at $8,496,669.44. This trade represents a 46.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.69% of the company’s stock.

Analyst Upgrades and Downgrades

AMGN has been the topic of a number of research analyst reports. Wolfe Research began coverage on Amgen in a report on Friday, November 15th. They issued a “peer perform” rating on the stock. UBS Group reduced their price objective on Amgen from $335.00 to $326.00 and set a “neutral” rating on the stock in a research note on Thursday, October 31st. Wells Fargo & Company dropped their target price on shares of Amgen from $335.00 to $280.00 and set an “equal weight” rating for the company in a research report on Friday, January 10th. Deutsche Bank Aktiengesellschaft reduced their price target on shares of Amgen from $305.00 to $285.00 in a research report on Wednesday, November 27th. Finally, William Blair reissued an “outperform” rating on shares of Amgen in a research report on Tuesday, November 12th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $314.09.

Amgen Stock Down 0.5 %

Shares of NASDAQ:AMGN opened at $295.06 on Thursday. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $346.85. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 9.62. The firm has a market cap of $158.60 billion, a PE ratio of 39.08, a price-to-earnings-growth ratio of 3.01 and a beta of 0.56. The company has a fifty day simple moving average of $272.96 and a 200 day simple moving average of $302.23.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. On average, equities research analysts anticipate that Amgen Inc. will post 20.59 EPS for the current fiscal year.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be given a $2.38 dividend. This is a positive change from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date of this dividend is Friday, February 14th. This represents a $9.52 annualized dividend and a dividend yield of 3.23%. Amgen’s dividend payout ratio (DPR) is presently 119.21%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.